ReviewCancer letters2010
Molecular mechanisms involved in farnesol-induced apoptosis.
Review in Cancer letters, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 193 citations in OpenAlex.
- Mesoporous silica nanoparticles functionalized with folic acid and zinc for enhanced targeted delivery of daunorubicin to breast cancer cells.Scientific reports · 2026Article
- Prenols and prenoic acids in metabolism, disease, and aging.Journal of lipid research · 2026Review
- Farnesol, the farnesol pathway, and the immune-gut-brain axis.Frontiers in pharmacology · 2026Review
- Cisplatin-loaded UiO-66-NHHeliyon · 2025Article
- Targeting the isoprenoid pathway in choleste biosynthesis: An approach to identify isoprenoid biosynthesis inhibitors.Archiv der Pharmazie · 2025Article
- Functional characterization of OR51B5 and OR1G1 in human lung epithelial cells as potential drug targets for non-type 2 lung diseases.Cell biology and toxicology · 2024Article
- Promising and challenging phytochemicals targeting LC3 mediated autophagy signaling in cancer therapy.Immunity, inflammation and disease · 2024Review
- Mononuclear phagocyte morphological response to chemoattractants is dependent on geranylgeranyl pyrophosphate.American journal of physiology. Endocrinology and metabolism · 2024Article
- Physiological adventures inMicrobiology and molecular biology reviews : MMBR · 2024Review
- Farnesol and Selected Nanoparticles (Silver, Gold, Copper, and Zinc Oxide) as Effective Agents Against Biofilms Formed by Pathogenic Microorganisms.Nanotechnology, science and applications · 2024Article
- Incorporation of Perillyl Alcohol into Lipid-Based Nanocarriers Enhances the Antiproliferative Activity in Malignant Glioma Cells.Biomedicines · 2023Article
- Unlocking Potentially Therapeutic Phytochemicals in Capadulla (Metabolites · 2023Article
- Farnesol brain transcriptomics in CNS inflammatory demyelination.Clinical immunology (Orlando, Fla.) · 2023Article
- Vasodilation promoted by (Heliyon · 2023Article
- FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer.Oncoimmunology · 2023Article
- Biological effects ofFrontiers in cellular and infection microbiology · 2023Article
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Folate-Targeted Curcumin-Loaded Niosomes for Site-Specific Delivery in Breast Cancer Treatment: In Silico and In Vitro Study.Molecules (Basel, Switzerland) · 2022Article
- Phytochemical Constituents and Antiproliferative Activities of Essential Oils from Four Varieties of MalaysianPlants (Basel, Switzerland) · 2022Article
- An Approach to Minimize Tumour Proliferation by Reducing the Formation of Components for Cell Membrane.Molecules (Basel, Switzerland) · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The isoprenoid alcohol farnesol is an effective inducer of cell cycle arrest and apoptosis in a variety of carcinoma cell types. In addition, farnesol has been reported to inhibit tumorigenesis in several animal models suggesting that it functions as a chemopreventative and anti-tumor agent in vivo. A number of different biochemical and cellular processes have been implicated in the growth-inhibitory and apoptosis-inducing effects of farnesol. These include regulation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase and CTP:phosphocholine cytidylyltransferase alpha (CCTalpha), rate-limiting enzymes in the mevalonate pathway and phosphatidylcholine biosynthesis, respectively, and the generation of reactive oxygen species. In some cell types the action of farnesol is mediated through nuclear receptors, including activation of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptors (PPARs). Recent studies have revealed that induction of endoplasmic reticulum (ER) stress and the subsequent activation of the unfolded protein response (UPR) play a critical role in the induction of apoptosis by farnesol in lung carcinoma cells. This induction was found to be dependent on the activation of the MEK1/2-ERK1/2 pathway. In addition, farnesol induces activation of the NF-kappaB signaling pathway and a number of NF-kappaB target genes. Optimal activation of NF-kappaB was reported to depend on the phosphorylation of p65/RelA by the MEK1/2-MSK1 signaling pathway. In a number of cells farnesol-induced apoptosis was found to be linked to activation of the apoptosome. This review provides an overview of the biochemical and cellular processes regulated by farnesol in relationship to its growth-inhibitory, apoptosis-promoting, and anti-tumor effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.